<DOC>
	<DOCNO>NCT03088813</DOCNO>
	<brief_summary>This open-label phase 3 comparative study ass safety , tolerability , efficacy irinotecan liposome injection compare topotecan ( IV ) patient small cell lung cancer progress platinum-based first-line therapy . The study conduct two part : 1a . dose determination irinotecan liposome injection 1b . preliminary safety efficacy 2. randomize , efficacy study irinotecan liposome injection versus topotecan</brief_summary>
	<brief_title>Study Irinotecan Liposome Injection ( ONIVYDE® ) Patients With Small Cell Lung Cancer</brief_title>
	<detailed_description>The study conduct two part : Part 1 ( 1a 1b ) : Part 1a : Open-label dose find study irinotecan liposome injection . Approximately 12 patient enrol Part 1a Objectives : - Describe safety tolerability irinotecan liposome injection monotherapy administer every 2 week - Determine irinotecan liposome injection monotherapy dose Part 1b Part 2 study Part 1b : Open-label parallel study irinotecan liposome injection IV topotecan . Approximately 50 patient enrol Part 1b Objectives : Describe follow treatment arm ( irinotecan liposome injection IV topotecan ) : - Progression free survival rate 12 week - Objective response rate ( ORR ) - Progression free survival ( PFS ) - Overall survival ( OS ) - Safety profile Part 2 : A randomized , efficacy study irinotecan liposome injection versus IV topotecan . Approximately 420 patient enrol part 2 . Part 2 objective : Detailed Primary &amp; Secondary objective section .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>General 1 . At least 18 year age . 2 . Able understand provide inform consent 3 . Consented participate translational research component trial ( provide blood archival tumor tissue ( available ) , specify section 9.6 ) , unless prohibit local regulation . 4 . Completed EORTCQLQC30 , EORTCQLQLC13 , EuroQoL five dimension , five level health status questionnaire ( EQ5D5L ) . 5 . ECOG performance status 0 1 . Disease Specific 6 . Histopathologically cytologically confirm small cell lung cancer accord International Association Study Lung Cancer ( IASLC ) histopathological classification . Mixed combine subtypes accord IASLC allow . 7 . Evaluable disease define RECIST v1.1 guideline ( patient nontarget lesion eligible ) . 8 . Progression firstline platinum base chemotherapy ( carboplatin cisplatin ) chemoradiation include platinumbased chemotherapy treatment limit extensive stage SCLC . 9 . Recovered effect prior chemotherapy , surgery , radiotherapy antineoplastic therapy ( recover grade 1 good , exception alopecia ) .Hematologic , Biochemical Organ Function Inclusion Criteria 10 . Adequate bone marrow reserve evidence : i. ANC &gt; 1,500 cells/μL ( 1.5 x 10⁹/L ) without use hematopoietic growth factor ; ii . Platelet count &gt; 100,000 cells/μL ( 100 x 10⁹/L ) ; iii . Hemoglobin &gt; 9 g/dL ; transfusion allow 11 . Adequate hepatic function evidence : i. Serum total bilirubin within normal range institution ii . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 x ULN ( ≤ 5 x ULN acceptable liver metastasis present ) iii . Serum albumin ≥3.0 g/dL ( ≥30 g/L ) 12 . Adequate renal function evidence serum creatinine ≤ 1.5 x ULN creatinine clearance ≥40 mL/min . Actual body weight used calculate creatinine clearance use CockcroftGault Equation ( except patient body mass index ( BMI ) &gt; 30 kg/m² lean body weight use instead 13 . ECG without clinically significant finding Patients must meet inclusion criterion list none follow exclusion criterion : General 1 . Any medical social condition deem Investigator likely interfere patient 's ability sign inform consent , cooperate participate study , interfere interpretation result 2 . Pregnant breast feeding ; female childbearing potential must test negative pregnancy time enrollment base urine serum pregnancy test . Both male female patient reproductive potential must agree use highly effective method birth control , study 4 month follow last dose study drug . Disease Specific 3 . Prior treatment regimen irinotecan , topotecan topoisomerase I inhibitor include investigational topoisomerase I inhibitors . 4 . Patients large cell neuroendocrine carcinoma . 5 . Patients one regimen prior cytotoxic chemotherapy 6 . More one line immunotherapy ( e.g . nivolumab , pembrolizumab , ipilimumab , atezolizumab , tremelimumab and/or durvalumab ) . One line immunotherapy define follow : monotherapy combination immunotherapy agent give either ( ) combination chemotherapy follow immunotherapy maintenance first line setting , ( ii ) maintenance follow response firstline chemotherapy ( iii ) immunotherapy give second line treatment follow progression . 7 . Patients history immunotherapy induce colitis . 8 . Any prior systemic treatment 1 line platinumcontaining regimen immunotherapy describe . 9 . Patients follow CNS metastasis : . Patients develop new progressive brain metastasis follow prophylactic and/or therapeutic cranial radiation ( whole brain stereotactic radiation ) . ii . Patients symptomatic CNS metastasis ( patient brain metastasis receive cranial radiotherapy eligible asymptomatic neurological symptom ≥2 week cranial radiotherapy corticosteroid treatment CNS metastasis . Patients asymptomatic brain metastasis eligible enrol directly study ) . iii . Patients carcinomatous meningitis . 10 . Unable discontinue use strong CYP3A4 UGTA1A1 inhibitor least 1 week strong CYP3A4 inducer least 2 week prior receive first dose irinotecan liposome injection . 11 . Presence another active malignancy . 12 . Investigational therapy administer within 4 week , within time interval less least 5 halflives investigational agent , whichever less , prior first schedule day dose study . Hematologic , Biochemical Organ Function Exclusion Criteria 13 . Severe arterial thromboembolic event ( e.g . myocardial infarction , unstable angina pectoris , stroke ) less 6 month inclusion . 14 . NYHA Class III IV congestive heart failure , ventricular arrhythmia , uncontrolled blood pressure . 15 . Active infection ( e.g . acute bacterial infection , tuberculosis , active hepatitis B active HIV ) investigator 's opinion might compromise patient 's participation trial affect study outcome . 16 . Known hypersensitivity component irinotecan liposome injection , liposomal product , topotecan . 17 . Clinically significant gastrointestinal disorder include hepatic disorder , bleeding , inflammation , occlusion , diarrhea &gt; grade 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>